Curasight Future Growth
Future criteria checks 2/6
Curasight is forecast to grow revenue at 105.6% per annum.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Biotechs earnings growth | 45.7% |
Revenue growth rate | 105.6% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 26 Aug 2024 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 66 | N/A | N/A | N/A | 1 |
12/31/2025 | 40 | N/A | N/A | N/A | 1 |
12/31/2024 | 7 | N/A | N/A | N/A | 1 |
9/30/2024 | N/A | -32 | -38 | -38 | N/A |
6/30/2024 | N/A | -32 | -34 | -34 | N/A |
3/31/2024 | N/A | -29 | -32 | -32 | N/A |
12/31/2023 | N/A | -26 | -30 | -30 | N/A |
9/30/2023 | N/A | -27 | -28 | -28 | N/A |
6/30/2023 | N/A | -25 | -28 | -28 | N/A |
3/31/2023 | N/A | -19 | -19 | -19 | N/A |
12/31/2022 | N/A | -18 | -24 | -16 | N/A |
9/30/2022 | N/A | -15 | -24 | -15 | N/A |
6/30/2022 | N/A | -13 | -22 | -12 | N/A |
3/31/2022 | N/A | -11 | -20 | -10 | N/A |
12/31/2021 | N/A | -8 | -10 | -7 | N/A |
9/30/2021 | N/A | -7 | -14 | -9 | N/A |
6/30/2021 | N/A | -7 | -13 | -8 | N/A |
3/31/2021 | N/A | -6 | -12 | -7 | N/A |
12/31/2020 | N/A | -6 | -12 | -7 | N/A |
12/31/2019 | N/A | -1 | -2 | -1 | N/A |
12/31/2015 | N/A | -1 | N/A | N/A | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if CURAS's forecast earnings growth is above the savings rate (1.2%).
Earnings vs Market: Insufficient data to determine if CURAS's earnings are forecast to grow faster than the Swedish market
High Growth Earnings: Insufficient data to determine if CURAS's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: CURAS's revenue (105.6% per year) is forecast to grow faster than the Swedish market (0% per year).
High Growth Revenue: CURAS's revenue (105.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CURAS's Return on Equity is forecast to be high in 3 years time